Astal Laboratories Ltd (512600)
Latest quarterly results (Q1 FY27)
In its latest reported quarter, Q1 FY27, Astal Laboratories' revenue was ₹101 Cr, and net profit ₹9.4 Cr; the operating margin was 12.1%.
| Q1 FY27 (₹ Cr) | Value | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹101 | — | -24.7% |
| Operating profit | ₹12.2 | — | +20.2% |
| Net profit | ₹9.4 | — | +22.7% |
| Operating margin | 12.1% | — | — |
📢 Recent Corporate Announcements
Astal Laboratories Ltd has disclosed the appointment of Ms. Ambika Kedia as Company Secretary of its material subsidiary, Sriven Pharmachem India Private Limited, effective September 28, 2026. The appointment was conducted in compliance with the provisions of the Companies Act, 2013. The role focuses on corporate secretarial and regulatory compliances, board meetings, and statutory filings. As this is an internal administrative appointment at a subsidiary level, there is no direct impact on the company's financial operations.
- Appointment of Ms. Ambika Kedia as Company Secretary of material subsidiary Sriven Pharmachem India Private Limited
- Appointment effective date: September 28, 2026
- Filing submitted under Regulation 30 of SEBI LODR on September 30, 2026
- Compliance move under the provisions of the Companies Act, 2013
Astal Laboratories Limited has scheduled a meeting of its Board of Directors on Friday, September 4, 2026. The agenda includes considering and approving the Notice for the 33rd Annual General Meeting (AGM) and setting the AGM date, time, and venue. Additionally, the Board will review and approve the Board Report for the financial year ended March 31, 2026, and appoint a voting scrutinizer.
- Board meeting scheduled for Friday, September 4, 2026
- Agenda includes approval of the Notice for the 33rd Annual General Meeting
- Board to approve the Directors' Report for FY ended March 31, 2026
- Appointment of Scrutinizer for AGM voting and remote e-voting to be considered
Astal Laboratories Limited has submitted its Statement of Deviation or Variation under Regulation 32 of SEBI (LODR) Regulations for the quarter ended June 30, 2026. The company confirmed there has been no deviation or variation in the utilization of funds raised through its preferential issue. The total amount raised was Rs. 306.00 Lakhs. The statement was reviewed by the Audit Committee and approved by the Board on August 14, 2026, with no adverse remarks.
- Total funds raised via preferential issue stood at Rs. 306.00 Lakhs
- Filing pertains to the quarter ended June 30, 2026
- Zero deviation or variation reported in the objects/utilization of proceeds
- Audit Committee and Board reviewed and passed the statement on August 14, 2026 without comments
Astal Laboratories reported consolidated revenue from operations of ₹100.94 Cr (₹10,093.58 Lakhs) for the quarter ended June 30, 2026. On a standalone basis, revenue grew 56.0% YoY to ₹39.51 Cr from ₹25.33 Cr, with standalone net profit increasing 77.4% YoY to ₹3.71 Cr compared to ₹2.09 Cr in the previous year quarter. The company's wholly owned subsidiary, Sriven Pharmachem India Private Limited, contributed ₹61.53 Cr in revenue and ₹5.71 Cr in net profit during the quarter. The business operates in a single segment focused on the manufacturing and trading of Active Pharmaceutical Ingredients (Bulk Drugs).
- Consolidated revenue from operations stood at ₹100.94 Cr (₹10,093.58 Lakhs) for Q1 ended June 30, 2026.
- Standalone revenue increased 56.0% YoY to ₹39.51 Cr from ₹25.33 Cr in the corresponding quarter of the previous year.
- Standalone net profit grew 77.4% YoY to ₹3.71 Cr (₹370.69 Lakhs) vs ₹2.09 Cr (₹208.96 Lakhs) in Q1 FY26.
- Subsidiary Sriven Pharmachem India contributed ₹61.53 Cr in revenue and ₹5.71 Cr in net profit for the quarter.
Astal Laboratories approved its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. On a consolidated basis, revenue from operations stood at ₹100.94 Cr, driven heavily by its wholly owned subsidiary Sriven Pharmachem India Pvt Ltd, which contributed ₹61.53 Cr in revenue and ₹5.71 Cr in PAT. Standalone revenue came in at ₹39.51 Cr with a net profit of ₹3.71 Cr, up 77.4% YoY compared to ₹2.09 Cr in the previous year quarter. Paid-up equity capital stood at ₹43.80 Cr.
- Consolidated revenue from operations reached ₹10,093.58 Lakhs (₹100.94 Cr) for Q1 ended June 30, 2026.
- Wholly owned subsidiary Sriven Pharmachem contributed ₹6,152.77 Lakhs in revenue and ₹571.48 Lakhs in net profit.
- Standalone revenue from operations rose 56.0% YoY to ₹3,951.47 Lakhs compared to ₹2,532.66 Lakhs in Q1 previous year.
- Standalone PAT surged to ₹370.69 Lakhs, up from ₹108.59 Lakhs in the preceding quarter and ₹208.96 Lakhs in Q1 previous year.
Astal Laboratories has scheduled a board meeting for August 14, 2026, to review and approve its unaudited financial results for the quarter ended June 30, 2026. The company is coming off a high-growth FY26 where revenue reached Rs 156 Cr, up from Rs 64 Cr in FY25, though operating margins significantly compressed to 8%. Investors should be aware of the low promoter holding, which stood at 4.53% as of June 2026. The trading window for designated persons remains closed until 48 hours after the meeting.
- Board meeting scheduled for August 14, 2026, to approve Q1 FY27 results.
- Trading window closed from July 01, 2026, until 48 hours after the meeting conclusion.
- Company reported TTM revenue of Rs 156 Cr against a market cap of Rs 94 Cr.
- Promoter holding has declined to 4.53% as of June 2026 from 18.19% in December 2025.
Financial Performance
Financial analysis data not yet available for this company.
Operational Drivers
Operational analysis data not yet available for this company.
Strategic Growth
Strategic growth analysis not yet available for this company.
External Factors
External factors analysis not yet available for this company.
Regulatory & Governance
Regulatory analysis not yet available for this company.
Risk Analysis
Risk analysis not yet available for this company.
